An Exploratory Study to Evaluate the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine With Sintilimab and Bevacizumab for BCLC-C Hepatocellular Carcinoma

NCT05617430 Phase 2 UNKNOWN

This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with sintilimab and bevacizumab in the first line treatment of patients with BCLC-C hepatocellular carcinoma.

Details

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 2
Status	UNKNOWN
Enrolment	43
Start date	2022-11-02
Completion	2024-06

Conditions

• Hepatocellular Carcinoma

Interventions

• HAIC
• Sintilimab
• Bevacizumab Biosimilar IBI305

Primary outcomes

• Progression free survival (PFS) per RECIST v1.1 — From baseline to primary completion date, about 18 months
  Defined as a duration from the date of initial treatment to disease progression or death of any cause

Countries

China